Please use this identifier to cite or link to this item:
doi:10.22028/D291-42493 | Title: | Gene Editing and Small Molecule Inhibitors of the RNA Binding Protein IGF2BP2/IMP2 Show its Potential as an Anti-Cancer Drug Target |
| Author(s): | Chanda, Shilpee Lepikhov, Konstantin Dahlem, Charlotte Schymik, Hanna S. Hoppstädter, Jessica Geber, An-Kristin Wagner, Konrad Kessler, Sonja M. Empting, Martin Kiemer, Alexandra |
| Language: | English |
| Title: | Frontiers in bioscience : a journal and virtual library. Landmark |
| Volume: | 29 |
| Issue: | 1 |
| Publisher/Platform: | IMR Press |
| Year of Publication: | 2024 |
| DDC notations: | 500 Science |
| Publikation type: | Journal Article |
| Abstract: | The RNA-binding protein IGF2BP2/IMP2/VICKZ2/p62 is an oncofetal protein that is overexpressed in several cancer entities. Employing IMP2 knockout colorectal cancer cells, we could show the important role of IMP2 in several hallmarks of cancer. This study aimed to functionally characterize IMP2 in lung (A549, LLC1) and hepatocellular carcinoma (HepG2, Huh7) cell lines to assess its role as a potential target for these cancer entities. |
| DOI of the first publication: | 10.31083/j.fbl2901041 |
| URL of the first publication: | https://www.imrpress.com/journal/FBL/29/1/10.31083/j.fbl2901041 |
| Link to this record: | urn:nbn:de:bsz:291--ds-424931 hdl:20.500.11880/38132 http://dx.doi.org/10.22028/D291-42493 |
| ISSN: | 2768-6698 2768-6701 |
| Date of registration: | 30-Jul-2024 |
| Third-party funds sponsorship: | Deutsche Forschungsgemeinschaft DFG |
| Sponsorship ID: | DFG(KI702) |
| Faculty: | NT - Naturwissenschaftlich- Technische Fakultät |
| Department: | NT - Pharmazie |
| Professorship: | NT - Prof. Dr. Anna Hirsch NT - Prof. Dr. Alexandra K. Kiemer |
| Collections: | SciDok - Der Wissenschaftsserver der Universität des Saarlandes |
Files for this record:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 2768-6698-29-1-041.pdf | 5,49 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License
